Valneva SE Sponsored ADR (NASDAQ:VALN) Stock Short Interest Report for October

Valneva SE Sponsored ADR (NASDAQ:VALN) was the target of a significant decline in short interest in October. As of October 30th, there was short interest totaling 47,986 shares, a decline of 75.0% from the October 15th total of 191,916 shares. Based on an average trading volume of 23,384 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.1% of the company’s stock are short sold.

Valneva Trading Up 0.9%

Shares of NASDAQ VALN opened at $5.92 on Thursday. The firm’s 50 day moving average price is $6.02 and its 200-day moving average price is $6.69. Valneva has a 52-week low of $4.75 and a 52-week high of $12.18. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16. The company has a market cap of $563.52 million, a PE ratio of -2.81 and a beta of 1.37.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The firm had revenue of $39.37 million for the quarter, compared to the consensus estimate of $44.17 million. On average, equities research analysts expect that Valneva will post -1.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. TD Cowen assumed coverage on Valneva in a report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price target for the company. Weiss Ratings raised Valneva from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $9.30.

Valneva Company Profile

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.